Generics Global Group of Eight (G8) Industry Guide 2017-2021

The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the G8 generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

– The G8 countries contributed $1,89,457.1 million in 2016 to the global generics industry, with a compound annual growth rate (CAGR) of 8.4% between 2012 and 2016. The G8 countries are expected to reach a value of $2,68,983.2 million in 2021, with a CAGR of 7.3% over the 2016-21 period.

– Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $1,01,790.0 million in 2016. This was followed by Japan and Germany, with a value of $45,850.0 and $18,657.1 million, respectively.

– The US is expected to lead the generics industry in the G8 nations with a value of $1,48,130.6 million in 2016, followed by Japan and Germany with expected values of $62,926.8 and $22,373.1 million, respectively.

Scope

– Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 generics market

– Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market

– Leading company profiles reveal details of key generics market players’ G8 operations and financial performance

– Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume

– Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country

Reasons to buy

- What was the size of the G8 generics market by value in 2016?

- What will be the size of the G8 generics market in 2021?

- What factors are affecting the strength of competition in the G8 generics market?

- How has the market performed over the last five years?

- How large is the G8 generics market in relation to its regional counterparts?

Table of Contents

Table of Contents

Introduction 14

What is this report about? 14

Who is the target reader? 14

How to use this report 14

Definitions 14

Group of Eight (G8) Generics 15

Industry Outlook 15

Generics in Canada 19

Market Overview 19

Market Data 20

Market Segmentation 22

Market outlook 23

Five forces analysis 25

Macroeconomic indicators 31

Generics in France 33

Market Overview 33

Market Data 34

Market Segmentation 36

Market outlook 37

Five forces analysis 39

Macroeconomic indicators 45

Generics in Germany 47

Market Overview 47

Market Data 48

Market Segmentation 50

Market outlook 51

Five forces analysis 53

Macroeconomic indicators 59

Generics in Italy 61

Market Overview 61

Market Data 62

Market Segmentation 64

Market outlook 65

Five forces analysis 67

Macroeconomic indicators 73

Generics in Japan 75

Market Overview 75

Market Data 76

Market Segmentation 78

Market outlook 79

Five forces analysis 81

Macroeconomic indicators 87

Generics in Russia 89

Market Overview 89

Market Data 90

Market Segmentation 92

Market outlook 93

Five forces analysis 95

Macroeconomic indicators 101

Generics in The United Kingdom 103

Market Overview 103

Market Data 104

Market Segmentation 106

Market outlook 107

Five forces analysis 109

Macroeconomic indicators 115

Generics in The United States 117

Market Overview 117

Market Data 118

Market Segmentation 120

Market outlook 121

Five forces analysis 123

Macroeconomic indicators 129

Company Profiles 131

Leading Companies 131

Appendix 161

Methodology 161

About MarketLine 162

List of Tables

List of Tables

Table 1: G8 generics industry, revenue($m), 2012-21

Table 2: G8 generics industry, revenue by country ($m), 2012-16

Table 3: G8 generics industry forecast, revenue by country ($m), 2016-21

Table 4: Canada generics market value: $ million, 2012-16

Table 5: Canada generics market volume: % of total pharma volume, 2012-16

Table 6: Canada generics market geography segmentation: $ million, 2016

Table 7: Canada generics market value forecast: $ million, 2016-21

Table 8: Canada generics market volume forecast: % of total pharma volume, 2016-21

Table 87: Canada size of population (million), 2012-16

Table 88: Canada gdp (constant 2005 prices, $ billion), 2012-16

Table 89: Canada gdp (current prices, $ billion), 2012-16

Table 90: Canada inflation, 2012-16

Table 91: Canada consumer price index (absolute), 2012-16

Table 92: Canada exchange rate, 2012-16

Table 9: France generics market value: $ million, 2012-16

Table 10: France generics market volume: % of total pharma volume, 2012-16

Table 11: France generics market geography segmentation: $ million, 2016

Table 12: France generics market value forecast: $ million, 2016-21

Table 13: France generics market volume forecast: % of total pharma volume, 2016-21

Table 14: France size of population (million), 2012-16

Table 15: France gdp (constant 2005 prices, $ billion), 2012-16

Table 16: France gdp (current prices, $ billion), 2012-16

Table 17: France inflation, 2012-16

Table 18: France consumer price index (absolute), 2012-16

Table 19: France exchange rate, 2012-16

Table 20: Germany generics market value: $ million, 2012-16

Table 21: Germany generics market volume: % of total pharma volume, 2012-16

Table 22: Germany generics market geography segmentation: $ million, 2016

Table 23: Germany generics market value forecast: $ million, 2016-21

Table 24: Germany generics market volume forecast: % of total pharma volume, 2016-21

Table 25: Germany size of population (million), 2012-16

Table 26: Germany gdp (constant 2005 prices, $ billion), 2012-16

Table 27: Germany gdp (current prices, $ billion), 2012-16

Table 28: Germany inflation, 2012-16

Table 29: Germany consumer price index (absolute), 2012-16

Table 30: Germany exchange rate, 2012-16

Table 31: Italy generics market value: $ million, 2012-16

Table 32: Italy generics market volume: % of total pharma volume, 2012-16

Table 33: Italy generics market geography segmentation: $ million, 2016

Table 34: Italy generics market value forecast: $ million, 2016-21

Table 35: Italy generics market volume forecast: % of total pharma volume, 2016-21

Table 36: Italy size of population (million), 2012-16

Table 37: Italy gdp (constant 2005 prices, $ billion), 2012-16

Table 38: Italy gdp (current prices, $ billion), 2012-16

Table 39: Italy inflation, 2012-16

Table 40: Italy consumer price index (absolute), 2012-16

Table 41: Italy exchange rate, 2012-16

Table 42: Japan generics market value: $ billion, 2012-16

Table 43: Japan generics market volume: % of total pharma volume, 2012-16

Table 44: Japan generics market geography segmentation: $ billion, 2016

Table 45: Japan generics market value forecast: $ billion, 2016-21

Table 46: Japan generics market volume forecast: % of total pharma volume, 2016-21

Table 47: Japan size of population (million), 2012-16

Table 48: Japan gdp (constant 2005 prices, $ billion), 2012-16

Table 49: Japan gdp (current prices, $ billion), 2012-16

Table 50: Japan inflation, 2012-16

Table 51: Japan consumer price index (absolute), 2012-16

Table 52: Japan exchange rate, 2012-16

Table 53: Russia generics market value: $ million, 2012-16

Table 54: Russia generics market volume: % of total pharma volume, 2012-16

Table 55: Russia generics market geography segmentation: $ million, 2016

Table 56: Russia generics market value forecast: $ million, 2016-21

Table 57: Russia generics market volume forecast: % of total pharma volume, 2016-21

Table 58: Russia size of population (million), 2012-16

Table 59: Russia gdp (constant 2005 prices, $ billion), 2012-16

Table 60: Russia gdp (current prices, $ billion), 2012-16

Table 61: Russia inflation, 2012-16

Table 62: Russia consumer price index (absolute), 2012-16

Table 63: Russia exchange rate, 2012-16

Table 64: United Kingdom generics market value: $ million, 2012-16

Table 65: United Kingdom generics market volume: % of total pharma volume, 2012-16

Table 66: United Kingdom generics market geography segmentation: $ million, 2016

Table 67: United Kingdom generics market value forecast: $ million, 2016-21

Table 68: United Kingdom generics market volume forecast: % of total pharma volume, 2016-21

Table 69: United Kingdom size of population (million), 2012-16

Table 70: United Kingdom gdp (constant 2005 prices, $ billion), 2012-16

Table 71: United Kingdom gdp (current prices, $ billion), 2012-16

Table 72: United Kingdom inflation, 2012-16

Table 73: United Kingdom consumer price index (absolute), 2012-16

Table 74: United Kingdom exchange rate, 2012-16

Table 75: United States generics market value: $ billion, 2012-16

Table 76: United States generics market volume: % of total pharma volume, 2012-16

Table 77: United States generics market geography segmentation: $ billion, 2016

Table 78: United States generics market value forecast: $ billion, 2016-21

Table 79: United States generics market volume forecast: % of total pharma volume, 2016-21

Table 80: United States size of population (million), 2012-16

Table 81: United States gdp (constant 2005 prices, $ billion), 2012-16

Table 82: United States gdp (current prices, $ billion), 2012-16

Table 83: United States inflation, 2012-16

Table 84: United States consumer price index (absolute), 2012-16

Table 85: United States exchange rate, 2012-15

Table 86: Apotex, Inc.: key facts

Table 93: Les Laboratoires Servier: key facts

Table 94: STADA Arzneimittel AG: key facts

Table 95: STADA Arzneimittel AG: key financials ($)

Table 96: STADA Arzneimittel AG: key financials (€)

Table 97: STADA Arzneimittel AG: key financial ratios

Table 98: Sanofi SA: key facts

Table 99: Sanofi SA: key financials ($)

Table 100: Sanofi SA: key financials (€)

Table 101: Sanofi SA: key financial ratios

Table 102: Sawai Pharmaceutical Co., Ltd.: key facts

Table 103: Sawai Pharmaceutical Co., Ltd.: key financials ($)

Table 104: Sawai Pharmaceutical Co., Ltd.: key financials (Â¥)

Table 105: Sawai Pharmaceutical Co., Ltd.: key financial ratios

Table 106: Daiichi Sankyo Co., Ltd.: key facts

Table 107: Daiichi Sankyo Co., Ltd.: key financials ($)

Table 108: Daiichi Sankyo Co., Ltd.: key financials (Â¥)

Table 109: Daiichi Sankyo Co., Ltd.: key financial ratios

Table 110: Abbott Laboratories: key facts

Table 111: Abbott Laboratories: key financials ($)

Table 112: Abbott Laboratories: key financial ratios

Table 113: Krka, d. d., Novo mesto: key facts

Table 114: Krka, d. d., Novo mesto: key financials ($)

Table 115: Krka, d. d., Novo mesto: key financials (€)

Table 116: Krka, d. d., Novo mesto: key financial ratios

Table 117: Mylan N.V.: key facts

Table 118: Mylan N.V.: key financials ($)

Table 119: Mylan N.V.: key financial ratios

Table 120: Novartis AG: key facts

Table 121: Novartis AG: key financials ($)

Table 122: Novartis AG: key financial ratios

Table 123: Teva Pharmaceutical Industries Limited: key facts

Table 124: Teva Pharmaceutical Industries Limited: key financials ($)

Table 125: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures

List of Figures

Figure 1: G8 generics industry, revenue($m), 2012-21

Figure 2: G8 Generics industry, revenue by country (%), 2016

Figure 3: G8 generics industry, revenue by country ($m), 2012-16

Figure 4: G8 generics industry forecast, revenue by country ($m), 2016-21

Figure 5: Canada generics market value: $ million, 2012-16

Figure 6: Canada generics market volume: % of total pharma volume, 2012-16

Figure 7: Canada generics market geography segmentation: % share, by value, 2016

Figure 8: Canada generics market value forecast: $ million, 2016-21

Figure 9: Canada generics market volume forecast: % of total pharma volume, 2016-21

Figure 10: Forces driving competition in the generics market in Canada, 2016

Figure 11: Drivers of buyer power in the generics market in Canada, 2016

Figure 12: Drivers of supplier power in the generics market in Canada, 2016

Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016

Figure 14: Factors influencing the threat of substitutes in the generics market in Canada, 2016

Figure 15: Drivers of degree of rivalry in the generics market in Canada, 2016

Figure 16: France generics market value: $ million, 2012-16

Figure 17: France generics market volume: % of total pharma volume, 2012-16

Figure 18: France generics market geography segmentation: % share, by value, 2016

Figure 19: France generics market value forecast: $ million, 2016-21

Figure 20: France generics market volume forecast: % of total pharma volume, 2016-21

Figure 21: Forces driving competition in the generics market in France, 2016

Figure 22: Drivers of buyer power in the generics market in France, 2016

Figure 23: Drivers of supplier power in the generics market in France, 2016

Figure 24: Factors influencing the likelihood of new entrants in the generics market in France, 2016

Figure 25: Factors influencing the threat of substitutes in the generics market in France, 2016

Figure 26: Drivers of degree of rivalry in the generics market in France, 2016

Figure 27: Germany generics market value: $ million, 2012-16

Figure 28: Germany generics market volume: % of total pharma volume, 2012-16

Figure 29: Germany generics market geography segmentation: % share, by value, 2016

Figure 30: Germany generics market value forecast: $ million, 2016-21

Figure 31: Germany generics market volume forecast: % of total pharma volume, 2016-21

Figure 32: Forces driving competition in the generics market in Germany, 2016

Figure 33: Drivers of buyer power in the generics market in Germany, 2016

Figure 34: Drivers of supplier power in the generics market in Germany, 2016

Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016

Figure 36: Factors influencing the threat of substitutes in the generics market in Germany, 2016

Figure 37: Drivers of degree of rivalry in the generics market in Germany, 2016

Figure 38: Italy generics market value: $ million, 2012-16

Figure 39: Italy generics market volume: % of total pharma volume, 2012-16

Figure 40: Italy generics market geography segmentation: % share, by value, 2016

Figure 41: Italy generics market value forecast: $ million, 2016-21

Figure 42: Italy generics market volume forecast: % of total pharma volume, 2016-21

Figure 43: Forces driving competition in the generics market in Italy, 2016

Figure 44: Drivers of buyer power in the generics market in Italy, 2016

Figure 45: Drivers of supplier power in the generics market in Italy, 2016

Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016

Figure 47: Factors influencing the threat of substitutes in the generics market in Italy, 2016

Figure 48: Drivers of degree of rivalry in the generics market in Italy, 2016

Figure 49: Japan generics market value: $ billion, 2012-16

Figure 50: Japan generics market volume: % of total pharma volume, 2012-16

Figure 51: Japan generics market geography segmentation: % share, by value, 2016

Figure 52: Japan generics market value forecast: $ billion, 2016-21

Figure 53: Japan generics market volume forecast: % of total pharma volume, 2016-21

Figure 54: Forces driving competition in the generics market in Japan, 2016

Figure 55: Drivers of buyer power in the generics market in Japan, 2016

Figure 56: Drivers of supplier power in the generics market in Japan, 2016

Figure 57: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016

Figure 58: Factors influencing the threat of substitutes in the generics market in Japan, 2016

Figure 59: Drivers of degree of rivalry in the generics market in Japan, 2016

Figure 60: Russia generics market value: $ million, 2012-16

Figure 61: Russia generics market volume: % of total pharma volume, 2012-16

Figure 62: Russia generics market geography segmentation: % share, by value, 2016

Figure 63: Russia generics market value forecast: $ million, 2016-21

Figure 64: Russia generics market volume forecast: % of total pharma volume, 2016-21

Figure 65: Forces driving competition in the generics market in Russia, 2016

Figure 66: Drivers of buyer power in the generics market in Russia, 2016

Figure 67: Drivers of supplier power in the generics market in Russia, 2016

Figure 68: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016

Figure 69: Factors influencing the threat of substitutes in the generics market in Russia, 2016

Figure 70: Drivers of degree of rivalry in the generics market in Russia, 2016

Figure 71: United Kingdom generics market value: $ million, 2012-16

Figure 72: United Kingdom generics market volume: % of total pharma volume, 2012-16

Figure 73: United Kingdom generics market geography segmentation: % share, by value, 2016

Figure 74: United Kingdom generics market value forecast: $ million, 2016-21

Figure 75: United Kingdom generics market volume forecast: % of total pharma volume, 2016-21

Figure 76: Forces driving competition in the generics market in the United Kingdom, 2016

Figure 77: Drivers of buyer power in the generics market in the United Kingdom, 2016

Figure 78: Drivers of supplier power in the generics market in the United Kingdom, 2016

Figure 79: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016

Figure 80: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016

Figure 81: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016

Figure 82: United States generics market value: $ billion, 2012-16

Figure 83: United States generics market volume: % of total pharma volume, 2012-16

Figure 84: United States generics market geography segmentation: % share, by value, 2016

Figure 85: United States generics market value forecast: $ billion, 2016-21

Figure 86: United States generics market volume forecast: % of total pharma volume, 2016-21

Figure 87: Forces driving competition in the generics market in the United States, 2016

Figure 88: Drivers of buyer power in the generics market in the United States, 2016

Figure 89: Drivers of supplier power in the generics market in the United States, 2016

Figure 90: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016

Figure 91: Factors influencing the threat of substitutes in the generics market in the United States, 2016

Figure 92: Drivers of degree of rivalry in the generics market in the United States, 2016

Figure 93: STADA Arzneimittel AG: revenues & profitability

Figure 94: STADA Arzneimittel AG: assets & liabilities

Figure 95: Sanofi SA: revenues & profitability

Figure 96: Sanofi SA: assets & liabilities

Figure 97: Sawai Pharmaceutical Co., Ltd.: revenues & profitability

Figure 98: Sawai Pharmaceutical Co., Ltd.: assets & liabilities

Figure 99: Daiichi Sankyo Co., Ltd.: revenues & profitability

Figure 100: Daiichi Sankyo Co., Ltd.: assets & liabilities

Figure 101: Abbott Laboratories: revenues & profitability

Figure 102: Abbott Laboratories: assets & liabilities

Figure 103: Krka, d. d., Novo mesto: revenues & profitability

Figure 104: Krka, d. d., Novo mesto: assets & liabilities

Figure 105: Mylan N.V.: revenues & profitability

Figure 106: Mylan N.V.: assets & liabilities

Figure 107: Novartis AG: revenues & profitability

Figure 108: Novartis AG: assets & liabilities

Figure 109: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 110: Teva Pharmaceutical Industries Limited: assets & liabilities

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports